We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Immune Cell Decreases Halt Merck’s Dual-Agent Antiretroviral HIV Study
Immune Cell Decreases Halt Merck’s Dual-Agent Antiretroviral HIV Study
Citing declining lymphocyte and T-cell counts in some patients, Merck has stopped its phase 2 trial of a dual-agent HIV antiretroviral regimen and is probing similar studies for this concerning safety signal.